Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study
Interleukin-6 (IL-6) was proposed to be associated with the severity of coronavirus disease 2019 (COVID-19). The present study aimed to explore the kinetics of IL-6 levels, validate this association in COVID-19 patients, and report preliminary data on the efficacy of IL-6 receptor blockade. We condu...
Saved in:
| Published in | Journal of translational medicine Vol. 18; no. 1; pp. 406 - 8 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
29.10.2020
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Interleukin-6 (IL-6) was proposed to be associated with the severity of coronavirus disease 2019 (COVID-19). The present study aimed to explore the kinetics of IL-6 levels, validate this association in COVID-19 patients, and report preliminary data on the efficacy of IL-6 receptor blockade.
We conducted a retrospective single-institutional study of 901 consecutive confirmed cases. Serum IL-6 concentrations were tested on admission and/or during hospital stay. Tocilizumab was given to 16 patients with elevated IL-6 concentration.
366 patients were defined as common cases, 411 patients as severe, and 124 patients as critical according to the Chinese guideline on diagnosis and treatment of COVID-19. The median concentration of IL-6 was < 1.5 pg/ml (IQR < 1.50-2.15), 1.85 pg/ml (IQR < 1.50-5.21), and 21.55 pg/ml (IQR 6.47-94.66) for the common, severe, and critical groups respectively (P < 0.001). The follow-up kinetics revealed serum IL-6 remained high in critical patients even when cured. An IL-6 concentration higher than 37.65 pg/ml was predictive of in-hospital death (AUC 0.97 [95% CI 0.95-0.99], P < 0.001) with a sensitivity of 91.7% and a specificity of 95.7%. In the 16 patients who received tocilizumab, IL-6 concentrations were significantly increased after administration, and survival outcome was not significantly different from that of propensity-score matched counterparts (n = 53, P = 0.12).
Serum IL-6 should be included in diagnostic work-up to stratify disease severity, but the benefit of tocilizumab needs further confirmation. Trial registration retrospectively registered. |
|---|---|
| AbstractList | Interleukin-6 (IL-6) was proposed to be associated with the severity of coronavirus disease 2019 (COVID-19). The present study aimed to explore the kinetics of IL-6 levels, validate this association in COVID-19 patients, and report preliminary data on the efficacy of IL-6 receptor blockade.
We conducted a retrospective single-institutional study of 901 consecutive confirmed cases. Serum IL-6 concentrations were tested on admission and/or during hospital stay. Tocilizumab was given to 16 patients with elevated IL-6 concentration.
366 patients were defined as common cases, 411 patients as severe, and 124 patients as critical according to the Chinese guideline on diagnosis and treatment of COVID-19. The median concentration of IL-6 was < 1.5 pg/ml (IQR < 1.50-2.15), 1.85 pg/ml (IQR < 1.50-5.21), and 21.55 pg/ml (IQR 6.47-94.66) for the common, severe, and critical groups respectively (P < 0.001). The follow-up kinetics revealed serum IL-6 remained high in critical patients even when cured. An IL-6 concentration higher than 37.65 pg/ml was predictive of in-hospital death (AUC 0.97 [95% CI 0.95-0.99], P < 0.001) with a sensitivity of 91.7% and a specificity of 95.7%. In the 16 patients who received tocilizumab, IL-6 concentrations were significantly increased after administration, and survival outcome was not significantly different from that of propensity-score matched counterparts (n = 53, P = 0.12).
Serum IL-6 should be included in diagnostic work-up to stratify disease severity, but the benefit of tocilizumab needs further confirmation. Trial registration retrospectively registered. Interleukin-6 (IL-6) was proposed to be associated with the severity of coronavirus disease 2019 (COVID-19). The present study aimed to explore the kinetics of IL-6 levels, validate this association in COVID-19 patients, and report preliminary data on the efficacy of IL-6 receptor blockade.BACKGROUNDInterleukin-6 (IL-6) was proposed to be associated with the severity of coronavirus disease 2019 (COVID-19). The present study aimed to explore the kinetics of IL-6 levels, validate this association in COVID-19 patients, and report preliminary data on the efficacy of IL-6 receptor blockade.We conducted a retrospective single-institutional study of 901 consecutive confirmed cases. Serum IL-6 concentrations were tested on admission and/or during hospital stay. Tocilizumab was given to 16 patients with elevated IL-6 concentration.METHODSWe conducted a retrospective single-institutional study of 901 consecutive confirmed cases. Serum IL-6 concentrations were tested on admission and/or during hospital stay. Tocilizumab was given to 16 patients with elevated IL-6 concentration.366 patients were defined as common cases, 411 patients as severe, and 124 patients as critical according to the Chinese guideline on diagnosis and treatment of COVID-19. The median concentration of IL-6 was < 1.5 pg/ml (IQR < 1.50-2.15), 1.85 pg/ml (IQR < 1.50-5.21), and 21.55 pg/ml (IQR 6.47-94.66) for the common, severe, and critical groups respectively (P < 0.001). The follow-up kinetics revealed serum IL-6 remained high in critical patients even when cured. An IL-6 concentration higher than 37.65 pg/ml was predictive of in-hospital death (AUC 0.97 [95% CI 0.95-0.99], P < 0.001) with a sensitivity of 91.7% and a specificity of 95.7%. In the 16 patients who received tocilizumab, IL-6 concentrations were significantly increased after administration, and survival outcome was not significantly different from that of propensity-score matched counterparts (n = 53, P = 0.12).RESULTS366 patients were defined as common cases, 411 patients as severe, and 124 patients as critical according to the Chinese guideline on diagnosis and treatment of COVID-19. The median concentration of IL-6 was < 1.5 pg/ml (IQR < 1.50-2.15), 1.85 pg/ml (IQR < 1.50-5.21), and 21.55 pg/ml (IQR 6.47-94.66) for the common, severe, and critical groups respectively (P < 0.001). The follow-up kinetics revealed serum IL-6 remained high in critical patients even when cured. An IL-6 concentration higher than 37.65 pg/ml was predictive of in-hospital death (AUC 0.97 [95% CI 0.95-0.99], P < 0.001) with a sensitivity of 91.7% and a specificity of 95.7%. In the 16 patients who received tocilizumab, IL-6 concentrations were significantly increased after administration, and survival outcome was not significantly different from that of propensity-score matched counterparts (n = 53, P = 0.12).Serum IL-6 should be included in diagnostic work-up to stratify disease severity, but the benefit of tocilizumab needs further confirmation. Trial registration retrospectively registered.CONCLUSIONSerum IL-6 should be included in diagnostic work-up to stratify disease severity, but the benefit of tocilizumab needs further confirmation. Trial registration retrospectively registered. Background Interleukin-6 (IL-6) was proposed to be associated with the severity of coronavirus disease 2019 (COVID-19). The present study aimed to explore the kinetics of IL-6 levels, validate this association in COVID-19 patients, and report preliminary data on the efficacy of IL-6 receptor blockade. Methods We conducted a retrospective single-institutional study of 901 consecutive confirmed cases. Serum IL-6 concentrations were tested on admission and/or during hospital stay. Tocilizumab was given to 16 patients with elevated IL-6 concentration. Results 366 patients were defined as common cases, 411 patients as severe, and 124 patients as critical according to the Chinese guideline on diagnosis and treatment of COVID-19. The median concentration of IL-6 was < 1.5 pg/ml (IQR < 1.50-2.15), 1.85 pg/ml (IQR < 1.50-5.21), and 21.55 pg/ml (IQR 6.47-94.66) for the common, severe, and critical groups respectively (P < 0.001). The follow-up kinetics revealed serum IL-6 remained high in critical patients even when cured. An IL-6 concentration higher than 37.65 pg/ml was predictive of in-hospital death (AUC 0.97 [95% CI 0.95-0.99], P < 0.001) with a sensitivity of 91.7% and a specificity of 95.7%. In the 16 patients who received tocilizumab, IL-6 concentrations were significantly increased after administration, and survival outcome was not significantly different from that of propensity-score matched counterparts (n = 53, P = 0.12). Conclusion Serum IL-6 should be included in diagnostic work-up to stratify disease severity, but the benefit of tocilizumab needs further confirmation. Trial registration retrospectively registered. Keywords: SARS-CoV-2, COVID-19, Interleukin-6, Tocilizumab Background Interleukin-6 (IL-6) was proposed to be associated with the severity of coronavirus disease 2019 (COVID-19). The present study aimed to explore the kinetics of IL-6 levels, validate this association in COVID-19 patients, and report preliminary data on the efficacy of IL-6 receptor blockade. Methods We conducted a retrospective single-institutional study of 901 consecutive confirmed cases. Serum IL-6 concentrations were tested on admission and/or during hospital stay. Tocilizumab was given to 16 patients with elevated IL-6 concentration. Results 366 patients were defined as common cases, 411 patients as severe, and 124 patients as critical according to the Chinese guideline on diagnosis and treatment of COVID-19. The median concentration of IL-6 was < 1.5 pg/ml (IQR < 1.50–2.15), 1.85 pg/ml (IQR < 1.50–5.21), and 21.55 pg/ml (IQR 6.47–94.66) for the common, severe, and critical groups respectively (P < 0.001). The follow-up kinetics revealed serum IL-6 remained high in critical patients even when cured. An IL-6 concentration higher than 37.65 pg/ml was predictive of in-hospital death (AUC 0.97 [95% CI 0.95–0.99], P < 0.001) with a sensitivity of 91.7% and a specificity of 95.7%. In the 16 patients who received tocilizumab, IL-6 concentrations were significantly increased after administration, and survival outcome was not significantly different from that of propensity-score matched counterparts (n = 53, P = 0.12). Conclusion Serum IL-6 should be included in diagnostic work-up to stratify disease severity, but the benefit of tocilizumab needs further confirmation. Trial registration retrospectively registered. Abstract Background Interleukin-6 (IL-6) was proposed to be associated with the severity of coronavirus disease 2019 (COVID-19). The present study aimed to explore the kinetics of IL-6 levels, validate this association in COVID-19 patients, and report preliminary data on the efficacy of IL-6 receptor blockade. Methods We conducted a retrospective single-institutional study of 901 consecutive confirmed cases. Serum IL-6 concentrations were tested on admission and/or during hospital stay. Tocilizumab was given to 16 patients with elevated IL-6 concentration. Results 366 patients were defined as common cases, 411 patients as severe, and 124 patients as critical according to the Chinese guideline on diagnosis and treatment of COVID-19. The median concentration of IL-6 was < 1.5 pg/ml (IQR < 1.50–2.15), 1.85 pg/ml (IQR < 1.50–5.21), and 21.55 pg/ml (IQR 6.47–94.66) for the common, severe, and critical groups respectively (P < 0.001). The follow-up kinetics revealed serum IL-6 remained high in critical patients even when cured. An IL-6 concentration higher than 37.65 pg/ml was predictive of in-hospital death (AUC 0.97 [95% CI 0.95–0.99], P < 0.001) with a sensitivity of 91.7% and a specificity of 95.7%. In the 16 patients who received tocilizumab, IL-6 concentrations were significantly increased after administration, and survival outcome was not significantly different from that of propensity-score matched counterparts (n = 53, P = 0.12). Conclusion Serum IL-6 should be included in diagnostic work-up to stratify disease severity, but the benefit of tocilizumab needs further confirmation. Trial registration retrospectively registered. Interleukin-6 (IL-6) was proposed to be associated with the severity of coronavirus disease 2019 (COVID-19). The present study aimed to explore the kinetics of IL-6 levels, validate this association in COVID-19 patients, and report preliminary data on the efficacy of IL-6 receptor blockade. We conducted a retrospective single-institutional study of 901 consecutive confirmed cases. Serum IL-6 concentrations were tested on admission and/or during hospital stay. Tocilizumab was given to 16 patients with elevated IL-6 concentration. 366 patients were defined as common cases, 411 patients as severe, and 124 patients as critical according to the Chinese guideline on diagnosis and treatment of COVID-19. The median concentration of IL-6 was < 1.5 pg/ml (IQR < 1.50-2.15), 1.85 pg/ml (IQR < 1.50-5.21), and 21.55 pg/ml (IQR 6.47-94.66) for the common, severe, and critical groups respectively (P < 0.001). The follow-up kinetics revealed serum IL-6 remained high in critical patients even when cured. An IL-6 concentration higher than 37.65 pg/ml was predictive of in-hospital death (AUC 0.97 [95% CI 0.95-0.99], P < 0.001) with a sensitivity of 91.7% and a specificity of 95.7%. In the 16 patients who received tocilizumab, IL-6 concentrations were significantly increased after administration, and survival outcome was not significantly different from that of propensity-score matched counterparts (n = 53, P = 0.12). Serum IL-6 should be included in diagnostic work-up to stratify disease severity, but the benefit of tocilizumab needs further confirmation. |
| ArticleNumber | 406 |
| Audience | Academic |
| Author | Hu, Sheng Zhang, Jing Liang, Gai Qian, Yu Cai, Qian Wang, Weida Ou, Wuling Wei, Shaozhong Ming, Fei Dong, Shuang Hao, Yiqun |
| Author_xml | – sequence: 1 givenname: Jing surname: Zhang fullname: Zhang, Jing – sequence: 2 givenname: Yiqun surname: Hao fullname: Hao, Yiqun – sequence: 3 givenname: Wuling surname: Ou fullname: Ou, Wuling – sequence: 4 givenname: Fei surname: Ming fullname: Ming, Fei – sequence: 5 givenname: Gai surname: Liang fullname: Liang, Gai – sequence: 6 givenname: Yu surname: Qian fullname: Qian, Yu – sequence: 7 givenname: Qian surname: Cai fullname: Cai, Qian – sequence: 8 givenname: Shuang surname: Dong fullname: Dong, Shuang – sequence: 9 givenname: Sheng surname: Hu fullname: Hu, Sheng – sequence: 10 givenname: Weida surname: Wang fullname: Wang, Weida – sequence: 11 givenname: Shaozhong surname: Wei fullname: Wei, Shaozhong |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33121497$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kl1vFCEUhiemxn7oH_DCTOJNb6YCw8Dghclm40eTJiaueksY5swu68ywAlO7_96z3Va7jRFCIIf3PHDgPc2ORj9Clr2k5ILSWryJlCkhC8IIjkrS4uZJdkK5VEVVS3H0YH2cnca4JoTxiqtn2XFZUka5kifZegFhGnI3Jgg9TD_cWIjcxdyMGGudNcmHvMMR4RqCS1sM54rQfGOSgzHF_JdLq3wx-7Io5v57wXC_A5ucH9_mJrd-5UPKY5ra7fPsaWf6CC_u5rPs24f3X-efiqvPHy_ns6vCVqJMBVdNbVVloKVQEtkJZmglSxBATFdDC8K21JQ1NJQyqSrLS0WbriFUWFtxW55ll3tu681ab4IbTNhqb5y-Dfiw1CYkZ3vQvBLKUFazRhHOaVO3ouGMEWyyVoYh692etZmaAVqLFQfTH0APd0a30kt_rWWluKooAs7vAMH_nCAmPbhooe_NCH6KGn9EcFrWNUHp60fStZ_CiE-FKoG3KoWSf1VLgwXgY3s81-6geiY4KQmXYse6-IcKewuDs2ijzmH8IOHVw0L_VHjvFBTUe4ENPsYAnbYumd0_I9n1mhK9M6Xem1KjKfWtKfUNprJHqff0_yT9BoVA4Vc |
| CitedBy_id | crossref_primary_10_25259_SRJHS_17_2022 crossref_primary_10_3390_vaccines10111786 crossref_primary_10_4103_jcsr_jcsr_10_21 crossref_primary_10_1016_j_ijid_2022_06_035 crossref_primary_10_3390_jcm13102936 crossref_primary_10_1080_11101849_2023_2192099 crossref_primary_10_3390_jcm11112958 crossref_primary_10_1063_5_0198047 crossref_primary_10_1017_erm_2021_9 crossref_primary_10_1186_s40249_021_00857_w crossref_primary_10_1111_ijcp_14867 crossref_primary_10_29333_ejgm_12191 crossref_primary_10_3389_fimmu_2021_658896 crossref_primary_10_3390_diagnostics11091582 crossref_primary_10_1038_s41398_022_01883_4 crossref_primary_10_1016_j_cyto_2023_156357 crossref_primary_10_1007_s10238_021_00788_8 crossref_primary_10_1186_s13063_023_07128_z crossref_primary_10_3390_ijms22137135 crossref_primary_10_1055_s_0044_1779016 crossref_primary_10_1021_acs_analchem_2c04318 crossref_primary_10_3390_biomedicines9050556 crossref_primary_10_4103_ecdt_ECDT_48_22 crossref_primary_10_1186_s12929_022_00833_y crossref_primary_10_3389_fimmu_2023_1161135 crossref_primary_10_3389_fimmu_2022_801522 crossref_primary_10_1016_j_snr_2024_100213 crossref_primary_10_1007_s12291_022_01033_z crossref_primary_10_1097_CCE_0000000000000535 crossref_primary_10_1016_j_cyto_2021_155543 crossref_primary_10_1016_j_psyneuen_2021_105295 crossref_primary_10_1186_s13287_022_02812_4 crossref_primary_10_1515_cclm_2023_0183 crossref_primary_10_3390_microorganisms11020319 crossref_primary_10_2144_fsoa_2022_0082 crossref_primary_10_3390_biomedicines11010095 crossref_primary_10_1016_j_semcancer_2021_01_003 crossref_primary_10_1177_03000605211056846 crossref_primary_10_1186_s12979_022_00271_2 crossref_primary_10_3389_fmed_2022_811176 crossref_primary_10_5005_jp_journals_10071_24075 crossref_primary_10_1016_j_advms_2022_07_003 crossref_primary_10_1016_j_cyto_2021_155755 crossref_primary_10_1186_s12974_021_02304_x crossref_primary_10_20473_jr_v9_I_2_2023_108_116 crossref_primary_10_1055_s_0042_1759567 crossref_primary_10_1042_BSR20203584 crossref_primary_10_3390_covid2090088 crossref_primary_10_2217_bmm_2020_0422 crossref_primary_10_1016_j_intimp_2021_108137 crossref_primary_10_1017_cts_2021_805 crossref_primary_10_2174_1567205019666220908084559 crossref_primary_10_1016_j_intimp_2021_107684 crossref_primary_10_3390_ijms23137314 crossref_primary_10_1016_j_ebiom_2022_104414 crossref_primary_10_1002_VIW_20210003 crossref_primary_10_3390_pathogens11050563 crossref_primary_10_1093_ofid_ofac423 crossref_primary_10_2217_fvl_2020_0316 crossref_primary_10_28996_2618_9801_2024_3_334_349 crossref_primary_10_1007_s10989_022_10366_5 crossref_primary_10_1038_s42255_022_00538_4 crossref_primary_10_4103_roaic_roaic_18_22 crossref_primary_10_1002_eji_202048922 crossref_primary_10_1002_bit_28358 crossref_primary_10_4103_amsr_amsr_3_23 crossref_primary_10_2478_rrlm_2021_0022 crossref_primary_10_1016_j_intimp_2021_108192 crossref_primary_10_1155_2022_4461647 crossref_primary_10_3390_v13071381 crossref_primary_10_56016_dahudermj_1220959 crossref_primary_10_3390_covid2050043 crossref_primary_10_4103_japt_japt_6_22 crossref_primary_10_1093_biomethods_bpac028 crossref_primary_10_12688_f1000research_125115_1 crossref_primary_10_12688_f1000research_125115_2 crossref_primary_10_3390_vaccines10040614 crossref_primary_10_1186_s12933_022_01569_7 crossref_primary_10_3892_ol_2024_14740 crossref_primary_10_1177_17534259211064602 crossref_primary_10_1016_j_jceh_2024_102496 crossref_primary_10_1186_s13054_023_04516_4 crossref_primary_10_1016_j_exger_2021_111507 crossref_primary_10_1186_s12887_024_05071_9 crossref_primary_10_1146_annurev_med_042220_012417 crossref_primary_10_1007_s12291_023_01121_8 crossref_primary_10_1093_trstmh_trab182 crossref_primary_10_1016_j_envres_2024_118451 crossref_primary_10_3390_biom11101425 crossref_primary_10_1136_postgradmedj_2021_139939 crossref_primary_10_1016_j_heliyon_2022_e11744 crossref_primary_10_1155_2023_6384208 crossref_primary_10_3389_fimmu_2022_795315 crossref_primary_10_1016_j_biosx_2022_100288 crossref_primary_10_3389_fnut_2022_832321 crossref_primary_10_3390_life11060561 crossref_primary_10_3390_ph15030345 crossref_primary_10_2147_IJGM_S357097 crossref_primary_10_4081_hls_2024_12723 crossref_primary_10_7759_cureus_27021 crossref_primary_10_1002_jcla_24809 crossref_primary_10_3390_ijms24098065 crossref_primary_10_1080_15257770_2023_2263490 crossref_primary_10_3390_v13050880 crossref_primary_10_3390_vaccines11040747 crossref_primary_10_15252_embj_2021109622 crossref_primary_10_1038_s41598_021_02489_4 crossref_primary_10_1186_s12916_022_02571_2 crossref_primary_10_1016_j_jviromet_2021_114224 crossref_primary_10_3389_fimmu_2022_830715 crossref_primary_10_1136_bmjgast_2021_000625 crossref_primary_10_1016_j_talanta_2023_124284 crossref_primary_10_1186_s12879_022_07610_0 crossref_primary_10_2174_0929867328666210506161543 |
| Cites_doi | 10.1056/NEJMoa2004500 10.1172/jci.insight.123158 10.12074/202003.00026 10.1002/jmv.25948 10.1101/2020.03.30.20048058 10.1016/S0140-6736(20)30305-6 10.1101/2020.03.01.20029769 10.1016/j.ccc.2006.03.003 10.1136/jitc-2020-001089 10.1101/2020.04.01.20047381 10.1002/jmv.25770 10.1101/2020.02.29.20029520 10.1093/cid/ciaa247 10.1016/j.jinf.2020.06.008 10.1136/bmj.m1091 10.1101/2020.02.25.20025643 10.1080/1744666X.2019.1629904 10.1172/JCI137244 10.1001/jama.2020.4783 10.1016/S0140-6736(20)30183-5 10.1182/blood-2008-05-155846 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2020 BioMed Central Ltd. 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2020 |
| Copyright_xml | – notice: COPYRIGHT 2020 BioMed Central Ltd. – notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2020 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12967-020-02571-x |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One Coronavirus Research Database ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals (DOAJ) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1479-5876 |
| EndPage | 8 |
| ExternalDocumentID | oai_doaj_org_article_4569a1282b90441b8d6b4220000789a2 PMC7594951 A640304760 33121497 10_1186_s12967_020_02571_x |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | China United States--US |
| GeographicLocations_xml | – name: China – name: United States--US |
| GrantInformation_xml | – fundername: Natural Science Foundation of Hubei Province grantid: 2017CFB459 – fundername: Combined Project of Health Commission of Hubei grantid: WJ2019H127 – fundername: ; grantid: 2017CFB459 – fundername: ; grantid: WJ2019H127 |
| GroupedDBID | --- 0R~ 29L 2WC 53G 5VS 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M CGR CUY CVF ECM EIF NPM PJZUB PPXIY PMFND 3V. 7T5 7XB 8FK AZQEC COVID DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c563t-49b8c95aed1e307f62a1573e6e0af8ede6cd1a38eb112795c4391bfb016cc54c3 |
| IEDL.DBID | M48 |
| ISSN | 1479-5876 |
| IngestDate | Wed Aug 27 01:04:09 EDT 2025 Thu Aug 21 18:25:50 EDT 2025 Fri Jul 11 08:36:27 EDT 2025 Fri Jul 25 05:32:55 EDT 2025 Tue Jun 17 21:08:14 EDT 2025 Tue Jun 10 20:20:24 EDT 2025 Mon Jul 21 05:51:50 EDT 2025 Tue Jul 01 03:51:15 EDT 2025 Thu Apr 24 23:10:22 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | COVID-19 SARS-CoV-2 Tocilizumab Interleukin-6 |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c563t-49b8c95aed1e307f62a1573e6e0af8ede6cd1a38eb112795c4391bfb016cc54c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12967-020-02571-x |
| PMID | 33121497 |
| PQID | 2462203697 |
| PQPubID | 43076 |
| PageCount | 8 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_4569a1282b90441b8d6b4220000789a2 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7594951 proquest_miscellaneous_2456413880 proquest_journals_2462203697 gale_infotracmisc_A640304760 gale_infotracacademiconefile_A640304760 pubmed_primary_33121497 crossref_citationtrail_10_1186_s12967_020_02571_x crossref_primary_10_1186_s12967_020_02571_x |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-10-29 |
| PublicationDateYYYYMMDD | 2020-10-29 |
| PublicationDate_xml | – month: 10 year: 2020 text: 2020-10-29 day: 29 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Journal of translational medicine |
| PublicationTitleAlternate | J Transl Med |
| PublicationYear | 2020 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | C Kotch (2571_CR23) 2019; 15 Y Gao (2571_CR8) 2020; 92 G Chen (2571_CR7) 2020; 130 A Zumla (2571_CR9) 2020; 395 2571_CR18 D Zhao (2571_CR16) 2020; 71 K Reinhart (2571_CR17) 2006; 22 2571_CR12 2571_CR13 2571_CR10 2571_CR11 2571_CR1 2571_CR14 2571_CR2 2571_CR20 T Conrozier (2571_CR24) 2020; 38 N Nishimoto (2571_CR22) 2008; 112 L Liu (2571_CR15) 2019; 4 C Huang (2571_CR5) 2020; 395 C Shen (2571_CR4) 2020; 323 T Chen (2571_CR6) 2020; 368 M Aziz (2571_CR21) 2020 PK Bhatraju (2571_CR3) 2020; 382 E Grifoni (2571_CR19) 2020; 81 V Montesarchio (2571_CR25) 2020; 8 |
| References_xml | – volume: 382 start-page: 2012 issue: 21 year: 2020 ident: 2571_CR3 publication-title: N Engl J Med. doi: 10.1056/NEJMoa2004500 – volume: 4 start-page: e123158 issue: 4 year: 2019 ident: 2571_CR15 publication-title: JCI Insight doi: 10.1172/jci.insight.123158 – ident: 2571_CR10 doi: 10.12074/202003.00026 – year: 2020 ident: 2571_CR21 publication-title: J Med Virol doi: 10.1002/jmv.25948 – ident: 2571_CR18 doi: 10.1101/2020.03.30.20048058 – volume: 395 start-page: e35 issue: 10224 year: 2020 ident: 2571_CR9 publication-title: Lancet doi: 10.1016/S0140-6736(20)30305-6 – ident: 2571_CR12 doi: 10.1101/2020.03.01.20029769 – volume: 22 start-page: 503 issue: 3 year: 2006 ident: 2571_CR17 publication-title: Crit Care Clin doi: 10.1016/j.ccc.2006.03.003 – volume: 38 start-page: 742 issue: 4 year: 2020 ident: 2571_CR24 publication-title: Clin Exp Rheumatol – volume: 8 start-page: e001089 issue: 2 year: 2020 ident: 2571_CR25 publication-title: J Immunother Cancer doi: 10.1136/jitc-2020-001089 – ident: 2571_CR20 doi: 10.1101/2020.04.01.20047381 – volume: 92 start-page: 791 issue: 7 year: 2020 ident: 2571_CR8 publication-title: J Med Virol doi: 10.1002/jmv.25770 – ident: 2571_CR2 – ident: 2571_CR11 – ident: 2571_CR14 doi: 10.1101/2020.02.29.20029520 – volume: 71 start-page: 756 issue: 15 year: 2020 ident: 2571_CR16 publication-title: Clin Infect Dis doi: 10.1093/cid/ciaa247 – volume: 81 start-page: 452 issue: 3 year: 2020 ident: 2571_CR19 publication-title: J Infect doi: 10.1016/j.jinf.2020.06.008 – volume: 368 start-page: m1091 year: 2020 ident: 2571_CR6 publication-title: BMJ doi: 10.1136/bmj.m1091 – ident: 2571_CR13 doi: 10.1101/2020.02.25.20025643 – volume: 15 start-page: 813 issue: 8 year: 2019 ident: 2571_CR23 publication-title: Expert Rev Clin Immunol doi: 10.1080/1744666X.2019.1629904 – volume: 130 start-page: 2620 issue: 5 year: 2020 ident: 2571_CR7 publication-title: J Clin Invest doi: 10.1172/JCI137244 – volume: 323 start-page: 1582 issue: 16 year: 2020 ident: 2571_CR4 publication-title: JAMA doi: 10.1001/jama.2020.4783 – ident: 2571_CR1 – volume: 395 start-page: 497 issue: 10223 year: 2020 ident: 2571_CR5 publication-title: Lancet doi: 10.1016/S0140-6736(20)30183-5 – volume: 112 start-page: 3959 issue: 10 year: 2008 ident: 2571_CR22 publication-title: Blood doi: 10.1182/blood-2008-05-155846 |
| SSID | ssj0024549 |
| Score | 2.5925362 |
| Snippet | Interleukin-6 (IL-6) was proposed to be associated with the severity of coronavirus disease 2019 (COVID-19). The present study aimed to explore the kinetics of... Background Interleukin-6 (IL-6) was proposed to be associated with the severity of coronavirus disease 2019 (COVID-19). The present study aimed to explore the... Abstract Background Interleukin-6 (IL-6) was proposed to be associated with the severity of coronavirus disease 2019 (COVID-19). The present study aimed to... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 406 |
| SubjectTerms | Aged Antibodies, Monoclonal, Humanized - administration & dosage Betacoronavirus Cardiovascular disease Clinical trials Cohort analysis Comorbidity Coronavirus Infections - blood Coronavirus Infections - drug therapy Coronaviruses COVID-19 COVID-19 Drug Treatment Cytokines Diagnosis Fatalities Female Health aspects Hospitals Humans Immunologic tests Immunosuppressive agents Infections Intensive care Interleukin 6 Interleukin 6 receptors Interleukin-6 - blood Kinetics Laboratories Male Medical imaging Medical prognosis Middle Aged Monoclonal antibodies Oxygen therapy Pandemics Patients Pneumonia, Viral - blood Pneumonia, Viral - drug therapy Propensity Score Retrospective Studies SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Software Tocilizumab Treatment Outcome Ventilators |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals (DOAJ) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NaxQxFA_Sg3gRa_0YW0sEwYOEbjL59LaWliLUg7XSW0gyWVyts7If0D_f9zIzyw6CXnqdJJDkffzem5f8Qshb11gADqdYmk0aJmWMzGWdGfLCSKmclAH_Q15-1hfX8tONutl56gvPhHX0wN3GnQDAuwBOVEQ3AeiOttFRClFKcNaF4n0B84ZkamDZg7RnuCJj9ckKUA0cAqZKgPGGs7sRDBW2_r998g4ojQ9M7iDQ-RPyuA8d6bSb8j55kNun5OFlXxw_ID_A7je_KBJALG_z5ue8ZZrOVzS0FAvTCdNrCjEqBTDM-GYdfKYA1LTnVl1R_ClLr6Zfrtjp4hsTdDip1X6ggeJTuss1LXy0z8j1-dnX0wvWP6XAktL1mkkXbXIq5IZnsOqZFoErU4NUJmFmc5N1anioLXhuLoxTCS_kxlmEgDAlJVP9nOy1iza_JNS4xFPKoQbQg-SQBxOdxXKfFSHZpCrCh531qecZx-cubn3JN6z2nTQ8SMMXafi7irzfjvndsWz8s_dHFNi2JzJklw-gN77XG_8_vanIOxS3RzuG6aXQX0eARSIjlp9qiVVjoycVORr1BPtL4-ZBYXxv_ysvpBZY4nWmIm-2zTgSz7S1ebHBPkpDCAEOtCIvOv3aLqmuuYDcFUabkeaN1jxuaeffCzu4AQODsPnVfWzSIXkk0GgAq4U7Invr5Sa_hiBsHY-Lvf0Bl0Eokg priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection (ProQuest) dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3daxQxEA9aQXwpfrtaJYLgg4TeZvPpi5zFUoT6YK3cW0iyuXra7tbbO-if78xe9tpF6OsmgWQnM7-ZTPIbQt7Z2gBwWMnifFIzIUJgNqnEkBdGCGmF8HgOefxNHZ2KrzM5ywduXb5WOdjE3lDXbcQz8n0uFMekmdWfLv8yrBqF2dVcQuMuuYfUZXilS8-uAy4Bwc_wUMao_Q6wDcwCBkyA9LpkVyMw6jn7_7fMN6BpfG3yBg4dPiS72YGk043EH5E7qXlM7h_nFPkT8hu0f31BkQZieZ7WfxYNU3TRUd9QTE9HDLIpeKoUIDFh5Tr4TAGuaWZY7SgezdKT6fcTdtD-ZJwO97Waj9RTLKi7XNGelfYpOT388uPgiOWCCixKVa2YsMFEK32qywS6PVfcl1JXIJuJn5tUJxXr0lcG7HfJtZURn-WGeQC3MEYpYvWM7DRtk14Qqm0sY0y-AuiDELH0OliDST_DfTRRFqQc_qyLmW0ci16cuz7qMMptpOFAGq6XhrsqyIftmMsN18atvT-jwLY9kSe7_9Auz1xWOwfuofUAwTzYCTh-wdQqCM77BK6xnhfkPYrboTbD9KLPjxJgkciL5aZKYO5Yq0lB9kY9QQvjuHnYMC5bgc5d79mCvN0240i82dakdo19pAJHAsxoQZ5v9td2SVVVcohgYbQe7bzRmsctzeJXzxGuQc3AeX55-7RekQcc1QGwmNs9srNartNrcLJW4U2vSf8AvL0iWQ priority: 102 providerName: ProQuest |
| Title | Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33121497 https://www.proquest.com/docview/2462203697 https://www.proquest.com/docview/2456413880 https://pubmed.ncbi.nlm.nih.gov/PMC7594951 https://doaj.org/article/4569a1282b90441b8d6b4220000789a2 |
| Volume | 18 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED-NTZr2MvFNYFRGQuIBBRrH8QcSQu20aULqhDqKKl4sx3GhrKTQD2n899ylSVnE4KUPsR3VuTv_7nz27wCem0IjcJgs9pNuEQuR57EJMsTECyNEZoRwtA85OJdnI_F-nI13oCl3VH_A5Y2hHdWTGi1mr65-_nqHBv-2MngtXy8Rs9DcKRBCBFdJjD7lHiKTIkMdCP2Hew-DoebizI3jDmA_TROOUYNq4VRF5__3on0NtdonKq9B1OltOKx9S9bbKMMd2AnlXdgf1Nnze_ANF4b1d0YMEYtZWF9Oy1iy6ZK5klHm2lP8zdCJZYiWgYra4WOGSM5q8tUlo11bdtEbXsTH808xZ81RrvINc4xq7S5WrCKsvQ-j05OPx2dxXWsh9plMV7EwufYmc6FIApr9RHKXZCpFsXXdRIciSF8kLtW4tCdcmczTjd18kqPH6H0mfPoAdst5GR4BU8Yn3geXIipi9Jg4lRtN-UDNndc-iyBpvqz1NRE51cOY2Sog0dJuBGNRMLYSjL2K4OV2zI8NDcd_e_dJYNueRKFdPZgvvtjaIi16jsYhOvPcdNEnzHUhc8F5ldvVxvEIXpC4Lake_j3v6vsKOEmizLI9KSitrGQ3gqNWTzRQ325uFMY2-m25kJxywEZF8GzbTCPp0FsZ5mvqk0n0MXCFjeDhRr-2U2rUNALV0rzWnNst5fRrRR-u0ALRr378z3c-gQNORoEIzc0R7K4W6_AUXa9V3oFbaqw6sNc_Of8w7FQbGJ3KxvB32P_8G1caKhs |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwEB6VrQS8IG4CBYwE4gFZ3TiOEyMhtC2ttrS7Qj1Q34zjeGGhZMseovwpfiMzObaNkPrW19iObM_1jceeAXip8xQNh465G3VzLmWWce2V55QXRspYS2npHHIwVP0j-fE4Pl6Bv81bGLpW2ejEUlHnE0dn5OtCKkFBM528P_3FqWoURVebEhoVW-z6P7_RZZu92_mA9H0lxPbW4Waf11UFuItVNOdSZ6nTsfV56JHBR0rYME4inGDXjlKfe-Xy0EYpKrFQJDp29DY1G2WIjZyLpYvwv9dgVUboynRgdWNr-Gn_PLsfulvN05xUrc_QmqIiIhcNsUUS8rOW-SurBPxvCy4Yw_ZFzQuWb_s23KohK-tVPHYHVnxxF64P6qD8PfiO-mbxk1HiiemJX_wYF1yx8YzZglFA3JFbzxAbMzTCnmrl4WeGAIHVOV1njA6D2UFv_4BvTj5zwZobYsVbZhmV8J3OWZkH9z4cXclmP4BOMSn8I2CJdqFz3kZobNEpDW2S6ZTCjKmwLnVxAGGzs8bV-c2pzMaJKf2cVJmKGgapYUpqmLMA3izHnFbZPS7tvUEEW_akzNzlh8n0q6kF3SAg1RaNvsh0F6FmluYqk0KUIeNUWxHAayK3If2B03O2fgaBi6RMXKanJEWrE9UNYK3VE-XetZsbhjG13pmZcykJ4MWymUbSXbrCTxbUJ1YIXVBxB_Cw4q_lkqIoFOgz4-ikxXmtNbdbivG3Mit5goKNcP3x5dN6Djf6h4M9s7cz3H0CNwWJBiIBodegM58u_FOEePPsWS1XDL5ctSj_Az0lYXY |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+interleukin-6+is+an+indicator+for+severity+in+901+patients+with+SARS-CoV-2+infection%3A+a+cohort+study&rft.jtitle=Journal+of+translational+medicine&rft.au=Zhang%2C+Jing&rft.au=Hao%2C+Yiqun&rft.au=Ou%2C+Wuling&rft.au=Ming%2C+Fei&rft.date=2020-10-29&rft.eissn=1479-5876&rft.volume=18&rft.issue=1&rft.spage=406&rft_id=info:doi/10.1186%2Fs12967-020-02571-x&rft_id=info%3Apmid%2F33121497&rft.externalDocID=33121497 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon |